SEBETRALSTAT (Ekterly®)

Clinical Indication

Acute attacks of hereditary angioedema (HAE) for FOC Scheme

Comments

Approved in accordance with MHRA Early Access to Medicines Scheme for the treatment of hereditary angioedema attacks in adult and adolescent patients aged 12 years and older.

Date of classification

September 2025

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.